The Vaccines and Related Biological Products Advisory Committee will have five more members than were present for the 22 October meeting on coronavirus vaccine development and approval issues.

The Belgian biotech has divested its drug discovery services unit in Croatia which was making a nice profit but was not a priority as Galapagos concentrates on setting up its commercial operations in Europe.

With the country accounting for 50% of global liver cancer cases, China aims the crosshairs with the help of novel therapies.

There are 18 people on the committee that will issue the first recommendations on COVID-19 vaccine development and licensure. Among the experts are a University of Michigan epidemiologist who will serve as acting chairman and seven temporary voting members, two of whom required conflict-of-interest waivers.